Ameritas Investment Company’s AtriCure ATRC Stock Holding History

Ameritas Investment Company’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9	Closed	-$590	–	814
2021 Q1	$590	Buy	+9	New	+$554	﹤0.01%	2152

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Ameritas Investment Company's ATRC Position: Q2 2021 in Review

Ameritas Investment Company sold out of AtriCure (ATRC) in Q2 2021, closing a stake of 9 shares — an estimated $590 sold.

Ameritas Investment Company first reported a position in ATRC in Q1 2021 and held it in 1 quarter. The position peaked at $590 in Q1 2021. 212 funds tracked by Wall St. Rank hold ATRC as of Q2 2021.

Ameritas Investment Company reported no remaining AtriCure position as of Q2 2021 after selling out during the quarter.
Ameritas Investment Company sold 9 AtriCure shares in Q2 2021, an estimated $590.
Ameritas Investment Company first reported a position in AtriCure in Q1 2021 and held it in 1 quarter.
Ameritas Investment Company's AtriCure position peaked at $590 in Q1 2021.
212 funds tracked by Wall St. Rank held AtriCure as of Q2 2021.

Based on Ameritas Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.